%PDF-1.3
%
2 0 obj
<>
endobj
24 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 54/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
8 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 53/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
17 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 53/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
22 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 55/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
12 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 54/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
25 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 55/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
9 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 54/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
18 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 54/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
6 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 54/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
20 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 53/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
10 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 55/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
15 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 54/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
13 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 55/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
21 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 54/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
4 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 55/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
3 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 54/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
5 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 53/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
14 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 53/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
23 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 53/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
19 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 55/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
16 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 55/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
1 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 53/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
7 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 55/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
11 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 53/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
26 0 obj
<>stream
2013-05-30T14:00:44+05:30
Arbortext Advanced Print Publisher 9.0.114/W
2014-11-19T07:49:57-08:00
Acrobat Distiller 8.1.0 (Windows); modified using iText 4.2.0 by 1T3XT
application/pdf
untitled
uuid:f595068c-f4dc-40e6-9e97-ab5dd77d86ee
uuid:93035b20-51a6-41d3-bfe1-cbe708993312
endstream
endobj
27 0 obj
<>stream
x+ |
endstream
endobj
28 0 obj
<>stream
xS**T0T0 Bih]D. r^j
endstream
endobj
29 0 obj
<>stream
x+ |
endstream
endobj
30 0 obj
<>stream
xS**T0T0 BiUD* :
endstream
endobj
31 0 obj
<>stream
x+ |
endstream
endobj
32 0 obj
<>stream
xS**T0T0 Bih] D. pa
endstream
endobj
33 0 obj
<>stream
x+ |
endstream
endobj
34 0 obj
<>stream
xS**T0T0 BiU !D. _e1
endstream
endobj
35 0 obj
<>stream
x+ |
endstream
endobj
36 0 obj
<>stream
xS**T0T0 BiUD* 8
endstream
endobj
37 0 obj
<>stream
x+ |
endstream
endobj
38 0 obj
<>stream
xS**T0T0 Bid]1D. pa
endstream
endobj
39 0 obj
<>stream
x+ |
endstream
endobj
40 0 obj
<>stream
xS**T0T0 BiU)D* 9V
endstream
endobj
41 0 obj
<>stream
x+ |
endstream
endobj
42 0 obj
<>stream
xS**T0T0 Bih]9D. qaj
endstream
endobj
43 0 obj
<>/XObject<>/ProcSet [/PDF /Text /ImageB /ImageC /ImageI]/Font<>>>/Thumb 52 0 R/MediaBox[0 0 612 792]/Rotate 0>>
endobj
53 0 obj
<>/ProcSet[/PDF/Text]/Font<>>>
endobj
45 0 obj
<>stream
/GS1 gs
BT
/F5 1 Tf
8.9663 0 0 8.9663 59.7543 725.7825 Tm
0 0 0 1 k
0 Tc
0 Tw
[(patients)-370.3(with)-369.4(OAG)]TJ
6.7246 0 0 5.9768 136.2897 729.751 Tm
(10,11)Tj
8.9663 0 0 8.9663 151.4267 725.7825 Tm
[(;)-369.6(\(4\))-367.2(there)-364.8(are)-366.8(abnormal)-371.8(levels)-369.3(of)-363.6(the)]TJ
-10.2241 -1.2203 TD
[(concentration)-316(of)-306.7(plasma)-312.6(endothelin-1)-314.1(\(ET-1\))-310.4(in)-304.1(patients)-313.4(with)]TJ
0 -1.2266 TD
[(OAG)-565.9(as)-569.9(compared)-566.8(with)-565.4(healthy)-571(control)-569.3(subjects)]TJ
6.7246 0 0 5.9768 264.4724 707.8676 Tm
(1215)Tj
8.9663 0 0 8.9663 281.3102 703.8423 Tm
[(;)-565.7(\(5\))]TJ
-24.7099 -1.2203 TD
[(platelet)-476.6(aggregation)-472(ability)-468.3(is)-466.4(remarkably)-469.9(increased)-472.1(in)-468.5(pa-)]TJ
T*
[(tients)-249.3(with)-243(OAG)-249.8(compared)-244.4(with)-243(that)-250.4(in)-240.9(normal)-247.7(subjects.)]TJ
6.7246 0 0 5.9768 279.3259 685.9274 Tm
(16)Tj
8.9663 0 0 8.9663 288.2267 681.9589 Tm
(As)Tj
-25.4813 -1.2266 TD
[(for)-396(oxidative)-401.3(stress,)-393.6(reactive)-396.1(oxygen)-396.4(species)-398.6(\(ROS\))-398.7(are)-392.1(pro-)]TJ
0 -1.2203 TD
[(duced)-354.3(as)-348.6(a)-347.3(consequence)-356.3(of)-351(normal)-355.2(aerobic)-351.6(metabolism.)-348.6(Un-)]TJ
T*
[(stable)-470.7(free)-468.9(radical)-470.6(species)-468.2(then)-468.7(attack)-471.6(cellular)-466.6(components)]TJ
0 -1.2266 TD
[(causing)-240.4(damage)-231.5(to)-237.2(lipids,)-234.2(proteins,)-244(and)-233.5(DNA)-236.7(that)-237.8(can)-236.1(initiate)]TJ
0 -1.2203 TD
[(a)-486.4(chain)-483.3(of)-477.5(reactions)-491.4(resulting)-480.2(in)-487.5(the)-484.3(onset)-482.1(of)-483.8(a)-480.1(variety)-483.5(of)]TJ
T*
(diseases,)Tj
6.7246 0 0 5.9768 94.0535 620.1636 Tm
(17)Tj
8.9663 0 0 8.9663 104.3716 616.1951 Tm
[(including)-411.1(GON.)]TJ
6.7246 0 0 5.9768 168.8881 620.1636 Tm
(1821)Tj
8.9663 0 0 8.9663 189.3543 616.1951 Tm
[(In)-403.8(fact,)-407.3(recent)-408.3(studies)-402.9(have)]TJ
-14.4542 -1.2203 TD
[(suggested)-477.7(that)-471.7(oxidative)-470.9(damage)-471.8(constitutes)-475.8(an)-470.8(important)]TJ
0 -1.2266 TD
[(pathologic)-406.7(step)-401.4(in)-398.9(inducing)-401.3(and)-404.2(maintaining)-401.6(the)-402.1(degenera-)]TJ
0 -1.2203 TD
[(tion)-509.7(of)-502.8(the)-509.6(trabecular)-508.9(meshwork,)-507.8(optic)-506.9(nerve,)-507(and)-505.4(RGCs.)]TJ
T*
[(Gherghel)-266.9(et)-265.9(al.,)-255.5(for)-263.2(example,)-266.1(reported)-261.7(that)-263.1(glaucoma)-267.2(patients)]TJ
0 -1.2266 TD
[(exhibit)-681.3(low)-671.8(levels)-679.1(of)-673.5(circulating)-682.9(glutathione,)-676.9(suggesting)]TJ
0 -1.2203 TD
[(compromised)-395.5(oxidative)-388.7(defence.)]TJ
6.7246 0 0 5.9768 189.4109 554.3998 Tm
(22)Tj
8.9663 0 0 8.9663 199.6157 550.4313 Tm
[(Ferreira)-395.1(et)-386.1(al.)-385.3(reported)-394.5(a)]TJ
-15.5986 -1.2203 TD
[(signicant)-546.6(decrease)-540.9(in)-538(total)-544.2(reactive)-541.5(antioxidant)-546.5(potential)]TJ
0 -1.2266 TD
[(and)-334.7(increased)-339.3(superoxide)-338.5(dismutase)-336.8(and)-334.7(glutathione)-345.2(perox-)]TJ
0 -1.2203 TD
[(idase)-589(activity)-587.3(in)-582.3(the)-585.5(aqueous)-586(humor)-587.5(from)-589.5(patients)-585.3(with)]TJ
T*
(glaucoma.)Tj
6.7246 0 0 5.9768 100.4031 510.5762 Tm
(23)Tj
8.9663 0 0 8.9663 111.9118 506.6077 Tm
[(Sorkhabi)-535.7(et)-537.8(al.)-530.8(reported)-539.9(that)-535(oxidative)-534.1(DNA)]TJ
-5.8171 -1.2203 TD
[(damage)-427.5(increases)-426.1(and)-429.5(total)-424.1(antioxidant)-432.7(status)-428.1(decreases)-428.5(in)]TJ
0 -1.2266 TD
[(the)-244(serum)-247.4(and)-239.9(aqueous)-244.6(humor)-246.1(of)-237.2(glaucoma)-248.2(patients.)]TJ
6.7246 0 0 5.9768 265.7763 488.6361 Tm
(24)Tj
8.9663 0 0 8.9663 274.6771 484.6676 Tm
(Taken)Tj
-23.9702 -1.2203 TD
[(together,)-489.2(ocular)-481.4(blood)-478.1(circulation)-485.3(and)-480.1(oxidative)-483.5(stress)-485.5(are)]TJ
T*
[(therefore)-343.3(additional)-332.1(therapeutic)-338.7(targets)-335.6(against)-340.9(OAG.)]TJ
1.1128 -1.2266 TD
[(Anthocyanins)-266.5(\(ACs\))-256.7(are)-259.3(kinds)-255.9(of)-256.2(polyphenols,)-264.6(rich)-253.5(in)-259.8(food)]TJ
-1.1128 -1.2203 TD
[(and)-423.2(beverages)-421.8(such)-422.7(as)-418.1(red)-420.9(wine,)-422.4(cocoa)-420.9(and)-416.9(berries,)-424.4(and)-416.9(it)]TJ
T*
[(is)-694(widely)-692.6(recognized)-699.3(that)-693(consumption)-700.1(of)-692.4(them)-696.8(serves)]TJ
0 -1.2266 TD
[(several)-309.1(health)-307.4(benets,)-306.2(such)-302.5(as)-304.3(antioxidative)-307.1(stress)-308.5(and)-303.1(anti-)]TJ
0 -1.2203 TD
[(inammatory)-353.9(effects.)]TJ
6.7246 0 0 5.9768 143.7732 411.9306 Tm
(25,26)Tj
8.9663 0 0 8.9663 162.085 407.9621 Tm
[(The)-354(ACs)-357(in)-348.4(black)-352.6(currants)-360.8(\(BC\))-351.9(in)]TJ
-11.4129 -1.2203 TD
[(particular)-471.5(have)-471.4(been)-469.2(implicated)-473.3(in)-468.5(improvement)-469.5(of)-471.1(visual)]TJ
0 -1.2266 TD
(functions.)Tj
6.7246 0 0 5.9768 98.4189 390.0471 Tm
[(27)-9.1(29)]TJ
8.9663 0 0 8.9663 118.3181 386.0219 Tm
[(In)-346.9(our)-339.9(initial)-346.3(clinical)-344.4(trial,)-339.5(we)-343(found)-346.1(that)-345.3(sys-)]TJ
-6.5316 -1.2203 TD
[(temic)-279(administration)-275.6(of)-268.8(BCACs)-277.9(\(50)-163.9(mg/day\))-271.6(to)-275.1(patients)-275.5(with)]TJ
T*
[(OAG)-243.5(\()]TJ
/F6 1 Tf
2.8769 0 TD
(n)Tj
/F7 1 Tf
.7208 0 TD
(=)Tj
/F5 1 Tf
.7208 0 TD
[(30\))-239.8(for)-244.2(6)-239.8(months)-242.8(caused)-244.6(a)-239.8(signicant)-243.1(increase)-247.8(in)-240.9(the)]TJ
-4.3185 -1.2203 TD
[(blood)-535(ows)-527.2(at)-531.1(the)-528.6(ONH)-534.1(\()]TJ
/F6 1 Tf
12.5004 0 TD
(P)Tj
/F7 1 Tf
.7714 0 TD
(<)Tj
/F5 1 Tf
.7145 0 TD
(0.05\).)Tj
6.7246 0 0 5.9768 206.022 357.1653 Tm
(30)Tj
8.9663 0 0 8.9663 217.474 353.1967 Tm
[(Furthermore,)-533.3(in)-531.7(the)]TJ
-17.5903 -1.2266 TD
[(subsequent)-245.5(randomized,)-243.4(placebo-controlled,)-242.2(double-masked,)]TJ
0 -1.2203 TD
[(24-month)-512.9(trial,)-503.9(we)-507.4(demonstrated)-511.5(that)-503.3(patients)-509.5(with)-508.5(OAG)]TJ
T*
[(administered)-407.8(with)-407.4(BCACs)-404.4(showed)-410.3(signicantly)-402.8(less)-410.7(deteri-)]TJ
0 -1.2266 TD
[(oration)-341.9(of)-338.4(mean)-335.5(deviation)-339.3(\(MD\))-336.2(and)-334.7(increased)-339.3(ocular)-335.9(blood)]TJ
0 -1.2203 TD
[(ows)-242.7(in)-234.5(comparison)-246.1(with)-236.6(placebo-treated)-242.8(patients)-243.9(during)-237.7(the)]TJ
T*
[(24-month)-354.8(trial)-355.5(period.)]TJ
6.7246 0 0 5.9768 147.685 291.4015 Tm
(31)Tj
8.9663 0 0 8.9663 157.5495 287.433 Tm
[(However,)-356.3(no)-347.6(signicant)-357(changes)-352.6(in)]TJ
-10.907 -1.2266 TD
[(systemic)-298.7(blood)-294.7(pressure,)-300.3(pulse)-292(rates,)-295.7(and)-296.8(IOP)-291(during)-300.9(the)-294.6(24-)]TJ
0 -1.2203 TD
[(month)-292.1(period)-295.8(were)-293(observed)-291(in)-291.4(either)-292.4(group,)-291.7(nor)-291.4(were)-293(there)]TJ
T*
[(any)-380.4(systemic)-380.8(or)-376.5(ocular)-380.2(side)-374.5(effects.)-384.1(These)-380.6(results)-381.6(suggested)]TJ
T*
[(that)-655.1(oral)-657.8(administration)-655(of)-654.5(BCACs)-657.3(may)-652.8(be)-655.6(a)-650.8(safe)-658.8(and)]TJ
0 -1.2266 TD
[(promising)-404.3(supplement)-408.5(for)-402.3(suppression)-410.3(of)-401.6(visual)-402(eld)-401.5(dete-)]TJ
0 -1.2203 TD
[(rioration)-504.2(in)-500.1(patients)-503.1(with)-495.9(OAG.)-499.3(Moreover,)-502.4(in)-500.1(addition)-499.8(to)]TJ
T*
[(their)-317.8(IOP)-316.3(control,)-319.3(the)-313.6(efcacy)-315.7(of)-319.4(the)-313.6(BCACs)-315.9(may)-317.6(have)-313.4(some)]TJ
0 -1.2267 TD
[(effects)-665.7(on)-657.4(ocular)-658.4(blood)-661.4(circulation)-656(and/or)-663.6(antioxidative)]TJ
0 -1.2203 TD
[(stress.)-343(Thus,)-340.8(it)-339.1(was)-343.9(of)-338.4(great)-340.1(interest)-344.8(to)-338.4(elucidate)-345.6(what)-340.1(kinds)]TJ
T*
[(of)-547(underlying)-539.8(mechanisms)-544.2(are)-543.9(involved)-542.4(in)-544.4(the)-541.2(BCAC-in-)]TJ
0 -1.2266 TD
[(duced)-335.3(benecial)-338.9(effects)-336.9(toward)-336.9(GON.)]TJ
1.1128 -1.2203 TD
[(Among)-648.2(the)-648.7(several)-650.5(possible)-650.4(mechanisms)-651.7(obtained)-649.3(by)]TJ
-1.1128 -1.2203 TD
[(BCACs,)-242.9(our)-232.5(study)-244.5(focused)-235.7(on)-240.1(the)-237.7(following)-241(biomarkers.)-239(ET-1)]TJ
0 -1.2266 TD
[(has)-352(been)-355.4(shown)-353.9(to)-351(be)-345.8(implicated)-353.1(in)-354.7(several)-353.4(ocular)-348.6(diseases,)]TJ
0 -1.2203 TD
[(including)-379.5(GON,)]TJ
6.7246 0 0 5.9768 124.0441 126.9921 Tm
(32)Tj
8.9663 0 0 8.9663 134.1354 123.0236 Tm
[(diabetic)-374.1(retinopathy,)]TJ
6.7246 0 0 5.9768 216.5102 126.9921 Tm
(33)Tj
8.9663 0 0 8.9663 226.6015 123.0236 Tm
[(retinal)-377.8(vein)-374.3(occlu-)]TJ
-18.6083 -1.2203 TD
[(sion,)-279.5(and)-271.5(retinal)-276.6(artery)-277.6(occlusion.)]TJ
6.7246 0 0 5.9768 190.7716 116.0504 Tm
(34)Tj
8.9663 0 0 8.9663 200.0125 112.0819 Tm
[(As)-274.6(for)-269.5(serum)-279(ET-1)-271.5(levels,)]TJ
-15.6429 -1.2203 TD
[(there)-295.2(are)-284.6(statistically)-292.8(signicant)-293.7(differences)-290.1(between)-294.1(patients)]TJ
0 -1.2266 TD
[(with)-439(glaucoma)-431.6(and)-429.5(control)-436.6(subjects.)]TJ
6.7246 0 0 5.9768 207.3826 94.1669 Tm
(1215)Tj
8.9663 0 0 8.9663 228.1322 90.1417 Tm
[(According)-435.1(to)-433.2(one)]TJ
-18.779 -1.2203 TD
(report,)Tj
/F6 1 Tf
3.4017 0 TD
[(in)-448.9(vitro)]TJ
/F5 1 Tf
3.1867 0 TD
[(,)-451.8(BCACs)-448.7(induced)-456.1(ET-dependent)-457.1(vessel)-449.3(dila-)]TJ
-6.5885 -1.2203 TD
[(tation)-383.2(in)-380(the)-383.1(bovine)-381.5(ciliary)-381.2(body.)]TJ
6.7246 0 0 5.9768 192.9259 72.2267 Tm
(35)Tj
8.9663 0 0 8.9663 203.0739 68.2583 Tm
[(Another)-385.1(factor)-382.6(affecting)]TJ
-15.9843 -1.2267 TD
[(ocular)-462.4(blood)-459.1(circulation)-460(is)-460.1(nitric)-459.8(oxide)-460.3(\(NO\),)-462.1(a)-454.8(ubiquitous)]TJ
0 -1.2203 TD
[(compound)-605.9(in)-594.9(the)-604.4(body)-596.3(that)-598.2(plays)-598.2(an)-597.3(important)-604.1(role)-601.3(in)]TJ
28.0042 75.7801 TD
[(vasodilation)-441.4(via)-433.7(the)-440(relaxation)-439.1(of)-439.5(vascular)-442.2(smooth)-438.2(muscle,)]TJ
0 -1.2203 TD
[(and)-315.7(hence)-315.7(in)-316.7(increasing)-316.1(circulation)-320.9(in)-310.4(the)-319.9(body.)]TJ
6.7246 0 0 5.9768 499.7479 718.8093 Tm
(36)Tj
8.9663 0 0 8.9663 509.329 714.8408 Tm
[(A)-311.2(number)]TJ
-22.1365 -1.2266 TD
[(of)-332(plant)-330.7(polyphenolic)-339.1(compounds,)-331.9(including)-335.3(AC,)-333.3(have)-332.3(been)]TJ
0 -1.2203 TD
[(shown)-391.9(to)-395.3(modulate)-400.1(NO)-388.7(levels)-394.6(and/or)-398.1(actions.)-392.6(NO)-395(being)-395(a)]TJ
T*
[(gaseous)-434.2(free)-430.9(radical)-426.4(has)-434.2(a)-429.5(half-life)-432.1(of)]TJ
/F7 1 Tf
17.5018 0 TD
(<)Tj
/F5 1 Tf
.7208 0 TD
[(15)-163.4(s)-431.3(and)-429.5(is)-434.8(rapidly)]TJ
-18.2226 -1.2266 TD
[(metabolized)-564.2(to)-559.7(nitrate)-570.7(\([NO)]TJ
6.7246 0 0 5.9768 427.8046 669.4865 Tm
(3)Tj
/F7 1 Tf
.6745 .9201 TD
(-)Tj
/F5 1 Tf
8.9663 0 0 8.9663 437.1589 670.9604 Tm
[(]\))-563.7(and)-562.3(nitrite)-568.4(\([NO)]TJ
6.7246 0 0 5.9768 516.8691 669.4865 Tm
(2)Tj
/F7 1 Tf
.6744 .9201 TD
(-)Tj
/F5 1 Tf
8.9663 0 0 8.9663 526.2235 670.9604 Tm
[(]\).)-560.3(As)]TJ
-24.0207 -1.2203 TD
[(such,)-596.3(serum)-595.2(nitrate)-596(and)-593.9(nitrite)-593.7(are)-594.5(usually)-596.7(measured)-597.6(to)]TJ
T*
[(evaluate)-479.1(serum)-475(levels)-476.8(of)-477.5(NO.)-473.8(In)-479.7(cases)-475.5(of)-477.5(oxidative)-477.2(stress,)]TJ
0 -1.2266 TD
[(advanced)-381.4(oxidation)-381.5(protein)-378.8(products)-383.3(\(AOPP\))-387.5(are)-379.5(the)-376.8(prod-)]TJ
0 -1.2203 TD
[(ucts)-571.5(of)-572.3(plasma)-571.8(protein)-574.9(oxidation,)-574.2(especially)-572.7(oxidation)-577.6(of)]TJ
T*
(albumin.)Tj
6.7246 0 0 5.9768 345.8267 620.1636 Tm
(37)Tj
8.9663 0 0 8.9663 355.8046 616.1951 Tm
[(Because)-358.3(of)-357.3(their)-355.7(rapid)-355.9(response)-364.7(to)-357.3(changes,)-355.6(they)]TJ
-5.0141 -1.2203 TD
[(are)-309.9(thought)-319.8(to)-313.1(be)-314.1(suitable)-317.5(for)-313.8(measuring)-315.2(short-term)-323.9(changes)]TJ
0 -1.2266 TD
[(in)-291.5(oxidative)-300.1(stress.)-298.8(Serum)-295.2(levels)-299.8(are)-297.3(known)-293.8(to)-294.1(correlate)-297.6(with)]TJ
0 -1.2203 TD
[(cardiovascular)-248.7(disease)-255.1(markers,)-253.6(and)-246.2(increase)-254.1(in)-247.2(subjects)-253.3(with)]TJ
T*
[(inammatory)-385.5(conditions)-383.9(such)-384.7(as)-386.5(ulcerative)-388.3(colitis,)-384.1(ankylos-)]TJ
0 -1.2266 TD
[(ing)-397(spondylitis,)-398.3(and)-391.6(renal)-399.1(failure.)]TJ
6.7246 0 0 5.9768 445.9464 565.3983 Tm
(38)Tj
8.9663 0 0 8.9663 456.2078 561.3731 Tm
[(Increased)-394.8(serum)-399.2(AOPP)]TJ
-16.2119 -1.2203 TD
[(levels)-306.1(are)-309.9(also)-310.6(reported)-312.3(in)-304.1(some)-311.4(patients)-313.4(with)-306.2(glaucoma.)]TJ
6.7246 0 0 5.9768 534.7841 554.3998 Tm
(39,40)Tj
8.9663 0 0 8.9663 310.8472 539.4896 Tm
[(Regarding)-807.1(antioxidant)-805.8(capacity,)-807(living)-809.5(organisms)-811.2(have)]TJ
0 -1.2266 TD
[(developed)-412.4(complex)-417.6(antioxidant)-413.8(systems)-417.3(to)-414.2(counteract)-418.1(ROS)]TJ
0 -1.2203 TD
[(and)-284.1(reduce)-288.7(their)-292.5(damage.)-285(These)-292(antioxidant)-287.3(systems)-290.8(include)]TJ
T*
[(several)-264.8(enzymes)-265.2(such)-270.9(as)-260.1(superoxide)-268.9(dismutase,)-270.1(catalase,)-265.2(and)]TJ
T*
[(glutathione)-553.9(peroxidase.)-560.8(They)-554.5(also)-550.9(include)-557.8(several)-555.7(macro-)]TJ
0 -1.2266 TD
[(molecules)-445.4(such)-447.9(as)-449.7(albumin,)-446.2(ceruloplasmin,)-450.6(and)-448.5(ferritin,)-445.6(as)]TJ
0 -1.2203 TD
[(well)-470.2(an)-477.1(array)-466.4(of)-477.5(small)-473.4(molecules,)-473.6(including)-474.4(ascorbic)-478.7(acid,)]TJ
T*
[(alpha-tocopherol,)-590.4(beta-carotene,)-589(reduced)-582.5(glutathione,)-588.4(uric)]TJ
0 -1.2266 TD
[(acid,)-248.5(and)-252.5(bilirubin.)-259(The)-252.9(sum)-253.1(of)-249.8(endogenous)-256.2(and)-252.5(food)-255.6(and/or)]TJ
0 -1.2203 TD
[(supplement-derived)-514.6(antioxidants)-509.9(represents)-508.4(the)-509.6(total)-506.3(anti-)]TJ
T*
[(oxidant)-337.3(activity)-334.4(of)-332(the)-338.9(system.)]TJ
6.7246 0 0 5.9768 431.4897 433.8707 Tm
(41)Tj
8.9663 0 0 8.9663 320.8251 418.9038 Tm
[(In)-309(the)-313.6(present)-316.8(study,)-317(we)-311.4(therefore)-318(examined)-318.8(the)-313.6(effects)-317.9(of)]TJ
-1.1128 -1.2203 TD
[(BCACs)-296.9(on)-290.7(the)-300.9(serum)-291.7(biomarkers,)-296(serum)-298(ET-1)-296.8(concentration,)]TJ
T*
[(NO,)-296.8(AOPP,)-294.6(and)-296.7(antioxidant)-300(capacity)-298.2(related)-297.9(to)-294.1(ocular)-298(blood)]TJ
0 -1.2266 TD
[(circulation)-396.7(and)-391.6(oxidative)-401.3(stress)-397(using)-393.4(serum)-399.2(specimens)-393.3(ob-)]TJ
0 -1.2203 TD
[(tained)-281.7(from)-279.7(BCAC-treated)-281(and)-277.8(placebo-treated)-287.1(patients)-281.8(with)]TJ
T*
[(OAG)-679.7(participating)-691.3(in)-683.5(a)-682.4(randomized,)-679.7(placebo-controlled,)]TJ
T*
[(double-masked,)-333.9(24-month)-335.9(trial.)]TJ
6.7246 0 0 5.9768 435.6849 357.1653 Tm
(31)Tj
/F3 1 Tf
9.9626 0 0 9.9626 310.8472 325.7574 Tm
[(Subjec)-10.1(ts)-332.8(and)-336.9(Methods)]TJ
/F5 1 Tf
8.9663 0 0 8.9663 320.8251 307.9558 Tm
[(A)-285.9(randomized,)-287.7(double-masked,)-289.6(placebo-controlled)-289.8(single-)]TJ
-1.1128 -1.2266 TD
[(center)-237.6(trial)-241.7(using)-241.6(38)-239.3(patients)-237.6(with)-243(OAG)-237.1(meeting)-243.1(the)-237.7(inclusion)]TJ
0 -1.2203 TD
[(and)-461.1(exclusion)-472.5(criteria)-469.2(described)-464(below)-467.5(was)-470.4(conducted)-467.7(be-)]TJ
T*
[(tween)-384.7(November)-391.7(1,)-381.8(2006,)-386.7(and)-385.3(March)-387.4(31,)-381.3(2010,)-386.7(in)-386.3(the)-383.1(glau-)]TJ
T*
[(coma)-391.2(clinic)-398.2(of)-395.3(the)-395.8(Department)-396.7(of)-395.3(Ophthalmology,)-399.8(Sapporo)]TJ
0 -1.2266 TD
[(Medical)-342.7(University)-348.2(Hospital.)]TJ
6.7246 0 0 5.9768 425.8204 257.1023 Tm
(31)Tj
8.9663 0 0 8.9663 435.6282 253.1338 Tm
[(The)-347.7(experimental)-347(protocol)-348.8(is)]TJ
-13.9167 -1.2203 TD
[(briey)-338.4(described)-337.5(below.)-337.6(This)-340(protocol)-336.1(was)-337.6(approved)-344.4(by)-337.6(the)]TJ
T*
[(Ethics)-320.8(Committee)-324.8(of)-325.7(the)-319.9(Sapporo)-323.1(Medical)-323.7(University)-322.9(School)]TJ
0 -1.2266 TD
[(of)-338.4(Medicine)-340.1(and)-341(conducted)-347.6(in)-335.7(accordance)-348.1(with)-337.8(the)-338.9(Declara-)]TJ
0 -1.2203 TD
[(tion)-294.7(of)-300.4(Helsinki.)-300.7(After)-300.1(an)-300.1(explanation)-297.7(of)-300.4(the)-300.9(studys)-298.3(purpose)]TJ
T*
[(and)-473.8(its)-473.2(protocol)-475.2(were)-476.3(provided,)-473.2(written)-478(informed)-472.9(consent)]TJ
0 -1.2266 TD
[(was)-464(obtained)-472.2(from)-469.4(all)-468.2(participants)-469.7(in)-468.5(our)-466.4(glaucoma)-469.5(clinic)]TJ
0 -1.2203 TD
[(before)-336.9(inclusion.)]TJ
/F11 1 Tf
9.9626 0 0 9.9626 310.8472 151.8236 Tm
[(Inclusion)-342.9(and)-335.7(exclusi)-10.1(on)-330(c)-6.5(riteria)]TJ
/F5 1 Tf
8.9663 0 0 8.9663 320.8251 133.9653 Tm
[(From)-309(among)-311.2(250)-314.7(eligible)-313.6(patients)-313.4(with)-312.5(OAG,)-309.6(a)-315.7(total)-310.3(of)-313.1(38)]TJ
-1.1128 -1.2203 TD
[(patients)-414.6(meeting)-420.2(the)-414.7(following)-411.7(inclusion)-420.4(and)-410.6(exclusion)-421.9(cri-)]TJ
T*
[(teria)-332.9(were)-337.2(enrolled)-332.9(in)-335.7(the)-332.5(study.)]TJ
/F6 1 Tf
1.1128 -2.447 TD
[(Inclusion)-408.2(criteria.)]TJ
/F5 1 Tf
8.264 0 TD
[(\(1\))-411.4(More)-406.8(than)-405.1(24)-410(months)-407.2(of)-407.9(treatment)]TJ
-9.3769 -1.2203 TD
[(by)-502(antiglaucoma)-501.7(drops)-502.3(and)-499.1(regularly)-504.9(receiving)-502.3(IOP)-506(mea-)]TJ
T*
[(surements)-328.4(at)-328.8(12-month)-329.1(intervals)-329.2(and)-328.4(the)-332.5(Humphrey)-331.1(visual)]TJ
0 -1.2267 TD
[(eld)-256(\(program)-254.1(302,)-253.9(SITA)-257.9(standard,)-254.1(Humphrey)-261.6(Instruments,)]TJ
0 -1.2203 TD
[(San)-330.2(Leandro,)-337.7(CA\))-337.2(at)-328.8(36-month)-341.7(intervals.)]TJ
/F3 1 Tf
-28.0042 78.4484 TD
[(EFFECT)-338(OF)-337.5(ANTHOCYANINS)-337.6(ON)-334.6(GLAUCOMA)-30962.6(481)]TJ
ET
endstream
endobj
54 0 obj
<>/ProcSet [/PDF /Text /ImageB /ImageC /ImageI]/XObject<>/Font<>>>/Thumb 60 0 R/MediaBox[0 0 612 792]/Rotate 0>>
endobj
61 0 obj
<>/ProcSet[/PDF/Text/ImageB]/XObject<>/Font<>>>
endobj
55 0 obj
<>stream
/GS1 gs
BT
/F5 1 Tf
8.9663 0 0 8.9663 72 568.3463 Tm
0 0 0 1 k
0 Tc
0 Tw
[(\(2\))-474.7(Early-to-moderate)-487.1(stages)-481.1(of)-477.5(GON)-476(\()-89(M)0(D)-474.4(greater)-479.8(than)]TJ
/F7 1 Tf
-1.1128 -1.2266 TD
(-)Tj
/F5 1 Tf
.7208 0 TD
[(12)-334.1(dB\))-328.9(in)-335.7(at)-335.1(least)-333.5(1)-334.6(eye.)]TJ
.392 -1.2203 TD
[(\(3\))-266(Best-corrected)-276.7(visual)-269.2(acuity)]TJ
/F7 1 Tf
13.8914 0 TD
(>)Tj
/F5 1 Tf
.7208 0 TD
[(0.6)-267.5(at)-265.5(the)-275.6(trial)-267(baseline)-274.7(in)]TJ
-15.7251 -1.2203 TD
[(at)-335.1(least)-333.5(1)-334.6(eye.)]TJ
1.1128 -1.2203 TD
[(\(4\))-487.3(Reliable)-492.8(performance)-492.4(on)-493(the)-490.6(Humphrey)-495.5(visual)-490.5(eld)]TJ
-1.1128 -1.2266 TD
[(testing)-481.4(302)-472.3(program)-474.9(\(xation)-476.9(loss)-476.8(of)]TJ
/F7 1 Tf
17.9571 0 TD
(<)Tj
/F5 1 Tf
.7145 0 TD
[(20%,)-477.8(and)-473.8(a)-473.7(false-)]TJ
-18.6716 -1.2203 TD
[(positive)-336.1(or)-338.6(false-negative)-339.5(response)-333.1(of)]TJ
/F7 1 Tf
16.996 0 TD
(<)Tj
/F5 1 Tf
.7208 0 TD
(33%\).)Tj
/F6 1 Tf
-16.604 -2.447 TD
[(Exclusion)-532.3(criteria.)]TJ
/F5 1 Tf
8.6245 0 TD
[(\(1\))-531.6(Ocular)-538.6(diseases)-534.6(other)-532(than)-537.9(OAG)]TJ
-9.7373 -1.2203 TD
[(and)-290.4(an)-281.1(early)-292.6(or)-281.7(mild)-285.8(senile)-289.8(cataract)-289.6(that)-288.4(would)-290.5(not)-284.8(inuence)]TJ
T*
[(the)-338.9(Humphrey)-331.1(visual)-338.8(eld)-331.9(testing.)]TJ
1.1128 -1.2266 TD
[(\(2\))-537.9(No)-540.2(other)-544.7(ocular,)-541.2(neurological,)-546.1(otolaryngological,)-543.8(or)]TJ
-1.1128 -1.2203 TD
[(systemic)-336.6(diseases)-338.6(affecting)-333.9(optic)-336.2(disc)-335.9(damage.)]TJ
1.1128 -1.2203 TD
[(\(3\))-550.5(History)-550.6(of)-553.3(cataract)-548.8(surgery)-550.3(within)-553.4(the)-553.8(previous)-549.1(24)]TJ
-1.1128 -1.2266 TD
(months.)Tj
1.1128 -1.2203 TD
[(\(4\))-335.6(History)-335.7(of)-332(glaucoma)-336.7(surgery.)]TJ
T*
[(\(5\))-335.6(Use)-331.4(of)-338.4(supplements.)]TJ
T*
[(\(6\))-335.6(History)-335.7(of)-332(drug)-331.9(or)-338.6(food)-331.5(allergies.)]TJ
/F11 1 Tf
9.9626 0 0 9.9626 62.022 360.1133 Tm
[(Met)-7(hods)]TJ
/F5 1 Tf
8.9663 0 0 8.9663 72 342.255 Tm
[(ACs)-521.4(\(25)-163.9(mg\))-520.9(extracted)-523.9(from)-520(BCs)-523(were)-520.6(packed)-519.6(into)-522.3(the)]TJ
-1.1128 -1.2203 TD
[(same)-251.2(capsules)-254.2(as)-253.7(placebos,)-255.3(making)-246.8(them)-254.2(indistinguishable)-258.5(to)]TJ
T*
[(patients)-243.9(or)-243.7(physicians.)-245.3(Based)-240.7(on)-240.1(the)-244(assignment)-242.4(list)-242.8(numbers,)]TJ
0 -1.2267 TD
[(subjects)-480.9(randomly)-482.8(received)-481.2(daily)-481.9(doses)-476.2(of)-483.8(BCACs)-480.3(\(2)-474.2(cap-)]TJ
0 -1.2203 TD
[(sules,)-383.4(50)-163.4(mg/day,)]TJ
/F6 1 Tf
8.2893 0 TD
(n)Tj
/F7 1 Tf
.7208 0 TD
(=)Tj
/F5 1 Tf
.7145 0 TD
[(19\))-385.2(or)-376.5(placebo)-383.8(capsules)-380.6(\()]TJ
/F6 1 Tf
11.1726 0 TD
(n)Tj
/F7 1 Tf
.7208 0 TD
(=)Tj
/F5 1 Tf
.7208 0 TD
[(19\))-378.9(for)-377(24)]TJ
-22.3388 -1.2203 TD
[(months.)-264.7(During)-267.7(the)-263(follow-up)-270.8(period,)-267.1(glaucoma)-260.9(medications)]TJ
T*
[(were)-337.2(not)-335.4(altered.)]TJ
1.1128 -1.2267 TD
.0112 Tc
[(For)-343.6(t)-1.9(he)-349.1(me)11.2(a)-7.2(s)-2.8(ure)11.2(m)-5.2(ent)-349.7(o)2.1(f)-343.4(s)-2.8(er)4.2(um)-340.4(leve)11.2(ls)-350.5(of)-349.7(ET-)11.2(1)-355.5(c)-.7(oncent)11.2(r)-8.9(a)-1(-)]TJ
-1.1128 -1.2203 TD
0 Tc
[(t)-13.1(i)-9.9(o)-9.1(n)-9.7(,)-546.7(N)-12.6(O)-9.4(,)-546.7(a)-12.2(n)-9.7(t)-13.1(i)-9.9(o)-9.1(x)-8.5(i)-9.9(d)-15.6(an)-15.5(t)-550.6(a)-12.2(ct)-18.7(i)-9.9(v)-13.4(i)-9.9(t)0(i)-16.6(e)-12.5(s)-14(,)-546.7(an)-21.9(d)-546.8(A)-7.7(O)-9.4(P)-14(P)-7.7(,)-546.7(t)-13.1(h)-9.7(e)-550(s)-7.6(u)-14(b)-10.7(j)-11.3(e)0(c)-18.1(t)-13.1(s)]TJ
T*
[(w)-7.9(e)-12.5(r)-13.3(e)-436.2(r)-13.3(e)0(q)-17(u)-14(es)-20.2(te)-19.3(d)-439.3(t)0(o)-445.8(r)-13.3(em)-16.4(a)-12.2(i)-9.9(n)-439.7(i)-9.9(n)-439.7(a)-435.8(s)-7.6(i)-16.2(tt)-19.9(i)-9.9(n)-9.7(g)-440.7(p)-7.7(o)-9.1(s)-14(i)-9.9(t)0(i)-16.6(o)-15.4(n)-433.3(q)-10.7(u)-14(i)-9.9(e)-12.5(t)0(l)-16.6(y)-440.7(fo)-22.2(r)]TJ
0 -1.2266 TD
.0105 Tc
[(30)-166.1(min.)-643.7(Their)-641.5(b)-.2(lood)-643.8(sa)10.5(m)-5.5(p)-3.5(les)-642.1(\()10.5(5)-172.8(m).3(L\))-647.6(were)-647(ta)10.5(k)-6.1(e)-2(n)-644.1(i).6(n)-644.1(t)10.5(h)-6(e)]TJ
0 -1.2203 TD
.0108 Tc
[(morning)-423.6(\()-2.3(9)10.8(1)-7.2(1)]TJ
/F9 1 Tf
7.0753 0 TD
.01 Tc
(a.m.)Tj
/F5 1 Tf
1.9348 0 TD
.0103 Tc
[(\))-426.4(a)-1.9(t)-426.5(t)-2.8(rial)-423.2(baseline)-425.9(a)-1.9(nd)-429(e)10.3(v)-9.3(ery)-424.1(6)-431.8(m)10.3(o)-9(nths)]TJ
-9.0101 -1.2203 TD
.0091 Tc
[(du)-4.9(ring)-431.6(t)9.1(h)-13.7(e)-427.1(2)9.1(4)-8.9(-)-4(m)9.1(o)-10.2(nt)-4(h)-424.2(t)-4(ria)-3.1(l)-424.4(p)-4.9(e)-3.4(riod.)-430.1(S)-2(e)-3.4(r)2.1(u)-4.9(m)-424.7(wa)-3.1(s)-428.5(t)9.1(h)-13.7(e)9.1(n)-436.8(i)-.8(mme)-3.4(-)]TJ
0 -1.2266 TD
0 Tc
[(d)-9.3(i)-9.9(a)-12.2(t)-13.1(el)-16.1(y)-472.3(s)-14(ep)-20.2(ar)-19.2(a)-12.2(t)0(e)-19.3(d)-470.9(b)-10.7(y)-472.3(c)-11.9(e)0(n)-15.9(t)-13.1(r)-13.3(i)-9.9(fu)-20.8(g)-10.7(a)0(t)-18.9(i)-9.9(o)-9.1(n)-471.3(a)-12.2(n)-9.7(d)-470.9(k)-10.7(e)-12.5(p)-7.7(t)-474.7(i)-9.8(n)-471.3(a)-473.7(fr)-20.1(e)-12.5(e)0(z)-18.4(e)-12.5(r)]TJ
0 -1.2203 TD
[(b)-10.7(e)-12.5(fo)-22.2(r)-7(e)-632.2(an)-15.5(a)-12.2(l)-9.9(y)-10.7(s)-7.6(i)-16.2(s)-7.6(.)-628.9(S)-11.1(e)-12.5(r)-7(u)-14(m)-623.5(E)-9.3(T)-15.6(-1)-638.6(co)-21(n)-9.7(c)-11.9(en)-22.3(tr)-20.1(at)-18.9(i)-9.9(o)-9.1(n)-9.7(s)-633.6(w)-7.9(e)-12.5(r)-7(e)-632.2(d)-9.3(e)-12.5(te)-19.3(r)-13.3(-)]TJ
T*
.0114 Tc
[(mined)-358.3(b).7(y)-359.7(a)-354.8(qua)11.4(n)-4.1(tita)11.4(t)-7.5(i)1.5(ve)-355.2(ET-1)-361.2(i)1.5(mm)11.4(u)-6.5(n)1.7(oassay)-353.4(kit)-362.1(\()11.4(R)-5.9(&)-2.6(D)-356.7(S).3(ys-)]TJ
T*
.0106 Tc
[(te)10.6(m)-5.8(s)-3.4(,)-346.4(M)-.8(innea)10.6(p)-9.2(olis,)-346.4(M)10.6(N)-7.1(\))-2.5(.)-346.4(F)-.1(or)-344.2(evalua)10.6(t)-8.3(i).7(on)-346.9(of)-350.3(serum)-347.4(l).7(evels)-344.8(o)-4.8(f)]TJ
0 -1.2266 TD
.0112 Tc
[(NO,)-409(i)1.3(ts)-413.7(stable)-412.3(me)11.2(t)-8.1(a)-1(bolite)11.2(s)-9(,)-409(n)1.5(itrit)11.2(e)-419.1([NO)]TJ
6.7246 0 0 5.9768 220.422 154.4882 Tm
0 Tc
(2)Tj
/F7 1 Tf
.6829 .9106 TD
(-)Tj
/F5 1 Tf
8.9663 0 0 8.9663 229.9464 155.9622 Tm
[(],)-433.3(an)-21.9(d)-420.3(n)-9.7(i)-9.9(t)-13.1(r)-7(i)-16.2(te)-430.3(a)-12.2(n)-9.7(d)]TJ
-18.7285 -1.2203 TD
.0108 Tc
[(nitrate)-368.5([)10.8(N)-8.6(O)]TJ
6.7246 0 0 5.9768 109.0771 143.5464 Tm
0 Tc
(2)Tj
/F7 1 Tf
.6829 .9106 TD
(-)Tj
8.9663 0 0 8.9663 120.0755 145.0204 Tm
(+)Tj
/F5 1 Tf
.7271 0 TD
.0126 Tc
(NO)Tj
6.7246 0 0 5.9768 141.1653 143.5464 Tm
0 Tc
(3)Tj
/F7 1 Tf
.6829 .9106 TD
(-)Tj
/F5 1 Tf
8.9663 0 0 8.9663 150.6897 145.0204 Tm
[(])-379.8(c)-11.9(o)-9.1(n)-9.7(c)-11.9(e)0(n)-22.3(t)0(r)-20.1(a)0(t)-18.9(i)-9.9(o)-9.1(n)-16(s)-374.4(w)-14.3(er)-19.6(e)-379.3(d)-9.3(et)-19.3(e)-12.5(r)-7(m)-10.2(i)-9.9(n)-9.7(e)-12.5(d)-376.1(b)-10.7(y)]TJ
-9.889 -1.2203 TD
[(N)-12.6(O)-9.4(2)-12.2(/)-9.3(NO)-15.7(3)-549.6(k)-10.7(i)-9.9(t)-13.1(-C)-19.6(I)-8.4(I)-545.9(\()-13.1(D)-7.7(o)-15.4(j)0(i)-21.1(n)-9.7(d)-9.3(o)-9.1(,)-546.7(T)]TJ
14.2329 0 TD
.0111 Tc
[(okyo,)-535.6(J)-2(apan\).)-535.6(AOPP)-534(assa)11.1(y)]TJ
-14.2329 -1.2266 TD
[(was)-243(p)3.5(erforme)11.2(d)-244.6(utiliz)11.2(i)-4.5(n)-4.8(g)-233.5(a)-241.2(qua)11.2(n)-4.3(tita)11.2(t)-7.7(i)1.3(ve)-235.3(kit)-242.2(\()11.2(T)-11.2(h)1.5(e)-235.3(O)-4.5(xiselect)11.2(T)-4.9(M)]TJ
0 -1.2203 TD
.0104 Tc
[(AOPP)-351.4(Assay)-348.1(k)-.3(it;)-346.6(C)-2.4(ell)-347.2(B)1.1(iolabs,)-352.9(I)2(nc.,)-352.9(Sa)10.4(n)-359.2(D)2.7(iego,)-352.9(C)10.4(A)-10.1(\))10.4(.)-359.7(A)2.7(OPP)]TJ
T*
.0111 Tc
[(concentrat)11.1(i)-5.5(o)-4.3(n)-466.5(w)3.2(as)-464.4(re)11.1(p)-9.1(o)2(rt)11.1(e)-8.2(d)-466.1(as)-464.4(mmol)-466.6(o)2(f)-469.9(C)-1.7(hlora)11.1(m)-4.9(ine-T/L.)]TJ
0 -1.2266 TD
.0091 Tc
[(Se)-3.4(ru)-4.9(m)-355.2(a)9.1(n)-6.4(t)-4(iox)-5.7(i)-.8(da)9.1(n)-12.8(t)-351.8(a)-3.1(c)9.1(t)-9.6(i)-.8(v)-4.3(i)-.8(t)9.1(i)-7.5(e)-3.4(s)-358.9(we)-3.4(re)-357.5(me)9.1(a)-9.3(s)1.5(u)-4.9(r)2.1(e)-3.4(d)-354.3(by)-355.7(a)9.1(n)-360.5(a)-3.1(n)-.6(t)-4(i)-.7(oxi)-7.1(-)]TJ
0 -1.2203 TD
.0107 Tc
[(dant)-451.3(a)10.7(s)-9.1(say)-449(k)0(it)-451.3(\()10.7(C)-8.9(ay)10.7(man)-447.9(C)-2.1(hemica)10.7(l)-453.9(C)-2.1(ompa)10.7(n)-4.8(y)0(,)-447.5(A)-3.3(nn)-447.9(Arbo)-4.7(r,)]TJ
T*
.0124 Tc
[(MI)4(\).)-540.6(A)4.7(l)2.5(l)-541.2(a).2(bove)-537.6(as)4.8(sa)12.4(ys)-545.3(w)4.5(e)-.1(r)5.4(e)-543.9(conduc)12.4(ted)-540.7(a)12.4(ccording)-542.1(to)-540.5(t)12.4(h)-4.1(e)]TJ
0 -1.2266 TD
.0111 Tc
[(pr)4.1(ocedures)-464.4(by)-467.5(the)-469.3(m).9(anufa)11.1(c)-6.7(turer)4.1(s)-2.9(.)-466(A)3.4(ll)-473(samples)-470.8(w)3.2(er)4.1(e)-469.3(a)-1.1(na-)]TJ
0 -1.2203 TD
.0109 Tc
[(lyze)10.9(d)-339.8(i)1(n)-333.9(d)1.6(uplicat)10.9(e)-343.5(a)10.9(t)-343.2(t)10.9(h)-5.6(e)-336.8(same)-330.4(time)10.9(.)]TJ
29.1107 58.215 TD
0 Tc
[(As)-211.4(a)-227.1(c)13.4(o)16.2(n)15.6(t)12.2(r)18.3(o)16.2(l)15.4(,)-224.2(h)0(e)28.3(a)13.1(l)15.4(t)18.5(hy)-216.5(v)18.2(o)16.2(l)15.4(u)0(n)26.9(t)18.5(e)12.7(e)12.8(r)18.3(s)-228.9(\()]TJ
/F6 1 Tf
13.98 0 TD
(n)Tj
/F7 1 Tf
.7082 0 TD
(=)Tj
/F5 1 Tf
.7018 0 TD
.2242 Tc
[(2)243.7(0)237.3(,m)239.3(a)237.3(l)239.6(e)243.3(/)240.2(f)236.4(e)237(m)239.3(a)243.7(l)239.6(e)237(,1)237.3(0)243.7(/)240.2(1)237.3(0)243.7(;)]TJ
-16.5028 -1.2266 TD
0 Tc
[(age,)-392.4(62.35)]TJ
/F7 1 Tf
4.5841 0 TD
()Tj
/F5 1 Tf
.7145 0 TD
[(12.55)-393(years\))-392(with)-394.7(age)-389.5(and)-391.6(gender)-397(matching)-390.9(the)]TJ
-5.2986 -1.2203 TD
[(patients)-338.7(with)-337.8(OAG)-332(were)-337.2(employed.)]TJ
/F11 1 Tf
9.9626 0 0 9.9626 313.0582 524.5227 Tm
[(Sta)-9(tistical)-339(analysi)-9.3(s)]TJ
/F5 1 Tf
8.9663 0 0 8.9663 323.0361 506.6644 Tm
[(Several)-761.5(observational)-756(data)-761.2(of)-755.7(serum)-759.6(levels)-755(of)-755.7(ET-1,)]TJ
-1.1128 -1.2203 TD
([NO)Tj
6.7246 0 0 5.9768 330.3495 494.192 Tm
(2)Tj
/F7 1 Tf
.666 .9201 TD
(-)Tj
/F5 1 Tf
8.9663 0 0 8.9663 339.7038 495.7227 Tm
[(],)-250([NO)]TJ
6.7246 0 0 5.9768 364.3653 494.192 Tm
(2)Tj
/F7 1 Tf
.666 .9201 TD
(-)Tj
8.9663 0 0 8.9663 375.1936 495.7227 Tm
(+)Tj
/F5 1 Tf
.7208 0 TD
(NO)Tj
6.7246 0 0 5.9768 395.9999 494.192 Tm
(3)Tj
/F7 1 Tf
.6745 .9201 TD
(-)Tj
/F5 1 Tf
8.9663 0 0 8.9663 405.3542 495.7227 Tm
[(],)-256.3(AOPP,)-250.3(and)-258.8(antioxidative)-256.5(activity)-252.2(of)]TJ
-10.2937 -1.2266 TD
[(the)-294.6(BCAC-treated)-300(and)-296.8(placebo-treated)-293.4(patients)-300.8(with)-293.5(OAG)-294(at)]TJ
0 -1.2203 TD
[(trial)-368.2(baseline)-363.3(were)-362.5(compared)-364.5(with)-363.1(those)-361.9(of)-363.6(healthy)-362.4(subjects)]TJ
T*
[(by)-369.2(one-way)-372.5(analysis)-370.6(of)-370(variance)-373.3(\(ANOVA\).)-372.9(Additionally,)-370.1(a)]TJ
0 -1.2266 TD
[(Tukeys)-332.4(multiple)-321.1(comparison)]TJ
/F6 1 Tf
13.2718 0 TD
[(post)-328.8(hoc)]TJ
/F5 1 Tf
3.6357 0 TD
[(test)-330.9(was)-324.9(performed)-322.5(to)]TJ
-16.9075 -1.2203 TD
[(evaluate)-314.7(differences)-309(between)-313.1(the)-307.3(experimental)-309.1(groups.)-312(After)]TJ
T*
[(normal)-1000.2(distribution)-1002.2(and)-998.6(homogeneity)-1002.6(of)-1002.3(data)-995.2(were)]TJ
ET
62.022 710.135 490.167 .22681 re
f
62.022 642.501 490.167 .22681 re
f
62.022 681.222 490.167 .22675 re
f
BT
/F9 1 Tf
8.9663 0 0 8.9663 95.1873 725.7825 Tm
(Table)Tj
/F5 1 Tf
3.0603 0 TD
(1.)Tj
/F9 1 Tf
1.7514 0 TD
[(Comparison)-335.9(of)-336.4(Serum)-333.6(Levels)-333(of)]TJ
/F5 1 Tf
15.7061 0 TD
[(ET-1,)-331.4(NO,)-334.7(AOPP,)]TJ
/F9 1 Tf
8.1186 0 TD
[(and)-338(Antioxidant)-334.7(Activity)-337.1(of)-330(Patients)]TJ
-26.9103 -1.1128 TD
(with)Tj
/F5 1 Tf
2.6177 0 TD
[(OAG)-332(\(BCAC)]TJ
/F9 1 Tf
6.089 0 TD
[(and)-338(Placebo)-333.4(Groups\))-334.2(at)-334(Trial)-333.5(Baseline)-334.3(with)-337.7(Those)-333.1(of)-336.4(Healthy)-332(Subjects)]TJ
/F6 1 Tf
-14.1317 -3.1551 TD
(Group)Tj
15.2445 1.1128 TD
(ET-1)Tj
-.6196 -1.1128 TD
(\(pg/mL\))Tj
7.7582 1.1128 TD
([NO)Tj
6.7246 0 0 5.9768 279.4393 696.0187 Tm
(2)Tj
/F7 1 Tf
.6745 .9106 TD
(-)Tj
/F6 1 Tf
8.9663 0 0 8.9663 288.7936 697.4927 Tm
(])Tj
-3.054 -1.1128 TD
(\()Tj
/F10 1 Tf
.3225 0 TD
(m)Tj
/F6 1 Tf
.5564 0 TD
(mol/L\))Tj
6.247 1.1128 TD
([NO)Tj
6.7246 0 0 5.9768 342.0283 696.0187 Tm
(2)Tj
/F7 1 Tf
.666 .9106 TD
(-)Tj
8.9663 0 0 8.9663 352.8566 697.4927 Tm
(+)Tj
/F6 1 Tf
.7145 0 TD
(NO)Tj
6.7246 0 0 5.9768 373.096 696.0187 Tm
(3)Tj
/F7 1 Tf
.666 .9106 TD
(-)Tj
/F6 1 Tf
8.9663 0 0 8.9663 382.4503 697.4927 Tm
(])Tj
-4.7864 -1.1128 TD
(\()Tj
/F10 1 Tf
.3225 0 TD
(m)Tj
/F6 1 Tf
.5501 0 TD
(mol/L\))Tj
8.7509 1.1128 TD
(AOPP)Tj
-.411 -1.1128 TD
(\()Tj
/F10 1 Tf
.3225 0 TD
(m)Tj
/F6 1 Tf
.5501 0 TD
(mol/L\))Tj
7.7456 1.1128 TD
(Antioxidant)Tj
-.999 -1.1128 TD
[(activity)-336.8(\()]TJ
/F10 1 Tf
3.6863 0 TD
(m)Tj
/F6 1 Tf
.5564 0 TD
(mol/L\))Tj
/F5 1 Tf
-52.0249 -2.0929 TD
[(BCACs)-334.8(\()]TJ
/F6 1 Tf
3.8633 0 TD
(n)Tj
/F7 1 Tf
.7208 0 TD
(=)Tj
/F5 1 Tf
.7145 0 TD
[(19\))-7258.2(3.18)]TJ
/F7 1 Tf
10.496 0 TD
()Tj
/F5 1 Tf
.7145 0 TD
(1.06)Tj
6.7246 0 0 5.9768 225.7511 672.718 Tm
(a)Tj
8.9663 0 0 8.9663 257.5558 668.7494 Tm
(7.50)Tj
/F7 1 Tf
1.9158 0 TD
()Tj
/F5 1 Tf
.7208 0 TD
[(2.66)-3826.8(15.84)]TJ
/F7 1 Tf
7.9922 0 TD
()Tj
/F5 1 Tf
.7145 0 TD
[(9.92)-4326.3(16.12)]TJ
/F7 1 Tf
8.4917 0 TD
()Tj
/F5 1 Tf
.7208 0 TD
[(7.50)-4421.2(0.204)]TJ
/F7 1 Tf
8.5865 0 TD
()Tj
/F5 1 Tf
.7208 0 TD
(0.042)Tj
-51.6708 -1.1128 TD
[(Placebo)-333.2(\()]TJ
/F6 1 Tf
4.034 0 TD
(n)Tj
/F7 1 Tf
.7145 0 TD
(=)Tj
/F5 1 Tf
.7208 0 TD
[(19\))-7087.5(3.44)]TJ
/F7 1 Tf
10.3253 0 TD
()Tj
/F5 1 Tf
.7145 0 TD
(0.84)Tj
6.7246 0 0 5.9768 225.7511 662.74 Tm
(a)Tj
8.9663 0 0 8.9663 257.5558 658.7715 Tm
(7.56)Tj
/F7 1 Tf
1.9158 0 TD
()Tj
/F5 1 Tf
.7208 0 TD
[(2.10)-3826.8(15.50)]TJ
/F7 1 Tf
7.9922 0 TD
()Tj
/F5 1 Tf
.7145 0 TD
[(12.64)-3826.3(16.06)]TJ
/F7 1 Tf
8.4917 0 TD
()Tj
/F5 1 Tf
.7208 0 TD
[(12.12)-3921.2(0.201)]TJ
/F7 1 Tf
8.5865 0 TD
()Tj
/F5 1 Tf
.7208 0 TD
(0.051)Tj
-51.6708 -1.1128 TD
[(Healthy)-340(subjects)-335.5(\()]TJ
/F6 1 Tf
7.9479 0 TD
(n)Tj
/F7 1 Tf
.7208 0 TD
(=)Tj
/F5 1 Tf
.7145 0 TD
[(20\))-3173.6(4.38)]TJ
/F7 1 Tf
6.4114 0 TD
()Tj
/F5 1 Tf
.7145 0 TD
[(1.03)-3548.6(7.53)]TJ
/F7 1 Tf
7.2144 0 TD
()Tj
/F5 1 Tf
.7208 0 TD
[(1.96)-3826.8(15.73)]TJ
/F7 1 Tf
7.9922 0 TD
()Tj
/F5 1 Tf
.7145 0 TD
[(4.09)-4326.3(16.00)]TJ
/F7 1 Tf
8.4917 0 TD
()Tj
/F5 1 Tf
.7208 0 TD
[(8.06)-4421.2(0.198)]TJ
/F7 1 Tf
8.5865 0 TD
()Tj
/F5 1 Tf
.7208 0 TD
(0.059)Tj
7.9702 0 0 7.9702 70.0157 630.7085 Tm
[(Values)-324.5(shown)-330.9(are)-325.7(mean)]TJ
/F7 1 Tf
10.8262 0 TD
()Tj
/F5 1 Tf
.7113 0 TD
(SD.)Tj
5.9774 0 0 5.3127 70.0157 625.266 Tm
(a)Tj
7.9702 0 0 7.9702 72.9637 621.6943 Tm
[(St)16.9(a)16.3(t)0(i)19.7(s)0(t)19.6(i)0(c)20.9(a)0(l)-271.7(d)0(i)24.3(f)0(f)18(e)0(r)20.8(e)0(n)22.8(c)0(e)-268.7(w)0(i)18.6(t)0(h)-272.6(h)0(e)22.8(a)0(l)19.9(t)16.1(hy)-270.2(su)20.3(bj)19.9(ec)23(ts)-272.1(\()]TJ
/F6 1 Tf
18.5653 0 TD
(P)Tj
/F7 1 Tf
.7611 0 TD
(<)Tj
/F5 1 Tf
.7042 0 TD
[(0.)24.5(05)18.4(,)-276.4(o)0(n)17.6(e)0(-)21.8(w)15(ay)-271(an)19.2(a)16.3(l)0(y)22.1(s)0(i)21.2(s)-288.2(o)14.6(f)-282.6(v)14.3(a)0(r)17.2(i)0(a)27(n)0(c)20.3(e)-286(\(A)25(NO)23.9(VA)22.7(\))-282.6(a)0(n)19.2(d)-278(Tu)23.3(ke)17(y)18.5()0(s)-274.3(m)14.3(ul)20.4(ti)19.7(pl)20.4(e)-278.9(c)0(o)17.7(m)14.3(pa)18.9(r)15.1(i)0(s)21.3(o)0(n)]TJ
/F6 1 Tf
34.5556 0 TD
[(p)16.3(o)0(s)18.2(t)-282.6(ho)26.5(c)]TJ
/F5 1 Tf
3.4926 0 TD
[(te)21.8(st)19.6(\).)]TJ
-58.4486 -1.1239 TD
[(ET-1,)-401.7(endothelin-1;)-407(NO,)-401.9(nitric)-410.8(oxide;)-404.7(AOPP,)-406(advanced)-397.9(oxidation)-407.5(protein)-408.8(product)10.9(s;)-415.2(OAG,)-405.2(open-an)11.4(gle)-413.3(glaucoma;)-400.4(BCACs)12.2(,)-411.5(black)-409.5(currant)]TJ
-1.003 -1.1239 TD
[(anthocyanins)11.3(;)-333.3(N)0(O)]TJ
5.9774 0 0 5.3127 125.8582 602.4755 Tm
(2)Tj
/F7 1 Tf
.6639 .9177 TD
(-)Tj
/F5 1 Tf
7.9702 0 0 7.9702 134.1354 603.7794 Tm
[(,)-333.3(nitrite;)-327(NO)]TJ
5.9774 0 0 5.3127 177.1086 602.4755 Tm
(3)Tj
/F7 1 Tf
.6639 .9177 TD
(-)Tj
/F5 1 Tf
7.9702 0 0 7.9702 185.3858 603.7794 Tm
[(,)-333.3(nitrate.)]TJ
ET
q
1 i
313.625 406.148 m
551.565 406.148 l
551.565 162.652 l
313.625 162.652 l
W n
q
238.023 0 0 243.496 313.625 162.652 cm
/Im1 Do
Q
Q
BT
/F8 1 Tf
8.9663 0 0 8.9663 313.0582 145.9275 Tm
[(FIG.)-286.2(1.)]TJ
/F5 1 Tf
4.0467 0 TD
[(The)-284.5(time)-286(course)-283.5(of)-287.8(mean)-284.9(serum)-285.4(endothelin-1)-288.8(\(ET-1\))]TJ
-4.0467 -1.1128 TD
[(concentrations.)-282.3(Mean)-267.2(serum)-272.7(ET-1)-265.2(concentrations)-279.4(in)-266.2(the)-275.6(black)]TJ
0 -1.1065 TD
[(currant)-694.6(anthocyanin)-699.6(\(BCAC\)-intake)-693.9(group)-693.5(\()]TJ
/F6 1 Tf
20.834 0 TD
(N)Tj
/F7 1 Tf
.9358 0 TD
(=)Tj
/F5 1 Tf
.7208 0 TD
[(19,)-691.1(lled)]TJ
-22.4906 -1.1128 TD
[(square\))-494.5(or)-490.3(placebo-intake)-496.7(group)-491.1(\()]TJ
/F6 1 Tf
15.5101 0 TD
(n)Tj
/F7 1 Tf
.7145 0 TD
(=)Tj
/F5 1 Tf
.7208 0 TD
[(19,)-488.8(lled)-487.2(circle\))-493.6(were)]TJ
-16.9454 -1.1128 TD
[(plotted)-315(at)-316.1(baseline)-312.7(and)-309.4(each)-318.2(time)-311.3(point)-315(of)-313.1(trial)-311.2(period)-314.8(\(6,)-306.4(12,)]TJ
T*
[(18,)-305.4(and)-303.1(24)-302.5(months\).)-309.5(Data)-304.4(expressed)-306.7(mean)]TJ
/F7 1 Tf
18.6273 0 TD
()Tj
/F5 1 Tf
.7208 0 TD
[(SD.)-306.3(*:)-300.8(signicant)]TJ
-19.3481 -1.1065 TD
[(difference)-250.8(between)-243.5(groups)-239.5(\()]TJ
/F6 1 Tf
12.1526 0 TD
(P)Tj
/F7 1 Tf
.7651 0 TD
(<)Tj
/F5 1 Tf
.7208 0 TD
[(0.05,)-238.3(2-way)-245.8(repeated-measure)]TJ
-13.6385 -1.1128 TD
[(analysis)-547.6(of)-547(variance\).)-547.4(#:)-546.2(signicant)-546.6(intergroups)-551(difference)]TJ
T*
[(between)-275.2(each)-267.6(time)-267(point)-270.8(and)-265.1(baseline)-268.4(\()]TJ
/F6 1 Tf
17.0655 0 TD
(P)Tj
/F7 1 Tf
.7714 0 TD
(<)Tj
/F5 1 Tf
.7208 0 TD
[(0.05,)-263.6(paired)]TJ
/F6 1 Tf
5.3618 0 TD
(t)Tj
/F5 1 Tf
.3225 0 TD
(-test\).)Tj
-24.242 -1.1065 TD
[(Mean)-595.9(serum)-588.9(ET-1)-587.7(concentrations)-595.6(in)-588.6(the)-591.8(healthy)-590(subjects)]TJ
0 -1.1128 TD
(\()Tj
/F6 1 Tf
.3288 0 TD
(n)Tj
/F7 1 Tf
.7145 0 TD
(=)Tj
/F5 1 Tf
.7208 0 TD
[(20\))-334.6(are)-335.2(indicated)-331.8(as)-335.9(a)-334.6(dotted)-332.1(line.)]TJ
/F3 1 Tf
-29.7619 78.442 TD
(482)Tj
37.4 0 TD
[(YOSHIDA,)-336.8(OHGURO,)-337.3(AND)-330.9(OHGURO)]TJ
ET
endstream
endobj
56 0 obj
<>stream
Adobe d C
s !1AQa"q2B#R3b$r%C4Scs5D'6Tdt&
EFVU(eufv7GWgw8HXhx)9IYiy*:JZjz ? Nlٳ~l~^yTibǙ'.mXYAu=Q$:2wc['?~]˞F4IY4fbÜƬX x͚_yQe{eORSH/q
eie } TOaxPݤru6U2b1|ٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lzc4[mN-GZgj3dPpfsd/;!P(Sٻs/,ٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳg> 2P0Y:͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6s d 1Dy쏖^lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳ@~OyҴ#A GZIӄjIvzQ})f{lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳ~'a#d|f͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lys0A,ٻI {j3a9% /56yM{=Qꔍ좑a0-Ff;YZedvQ$05
fu'f͛6lٳf} ̟/:͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳg7<sb?f͛6l%(I\$h* w$vwwYʹO*Od 1Dy쏖^lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛9riŰLf͛6l